Profile data is unavailable for this security.
About the company
Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.
- Revenue in GBP (TTM)183.15m
- Net income in GBP-33.58m
- Incorporated2001
- Employees290.00
- LocationAlliance Pharma PLCAvonbridge House, Bath RoadCHIPPENHAM SN15 2BBUnited KingdomGBR
- Phone+44 124 946 6966
- Fax+44 124 946 6977
- Websitehttps://www.alliancepharmaceuticals.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adimmune Corp | 40.42m | -14.83m | 234.21m | 564.00 | -- | 1.87 | -- | 5.80 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Cuorips Inc | 98.81k | -3.96m | 234.39m | 59.00 | -- | 8.15 | -- | 2,372.14 | -102.64 | -102.64 | 2.59 | 696.57 | 0.0032 | 0.83 | 11.65 | 325,813.60 | -12.67 | -- | -13.03 | -- | 56.90 | -- | -4,011.54 | -- | 36.15 | -14.12 | 0.00 | -- | -39.65 | -- | -39.84 | -- | -- | -- |
| Shanghai Serum Bio-Technology Co Ltd | 21.65m | 5.59m | 238.14m | 321.00 | 42.61 | 1.95 | -- | 11.00 | 0.4706 | 0.4706 | 1.82 | 10.30 | 0.1735 | 1.14 | 3.91 | 614,647.90 | 4.48 | 10.43 | 4.56 | 10.84 | 76.60 | 80.54 | 25.81 | 32.57 | 42.72 | -- | 0.004 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Panacea Biotec Ltd | 51.71m | -1.40m | 238.38m | 1.15k | -- | 3.04 | 127.01 | 4.61 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Seikagaku Corp | 197.19m | 10.36m | 238.59m | 988.00 | 22.12 | 0.5923 | 11.98 | 1.21 | 36.93 | 36.93 | 703.07 | 1,379.48 | 0.4679 | 1.93 | 4.88 | 38,827,940.00 | 2.46 | 0.4261 | 2.66 | 0.4678 | 47.98 | 54.18 | 5.25 | 0.9814 | 4.53 | -- | 0.0051 | 465.78 | 8.24 | 4.99 | -2.24 | -0.5224 | 30.28 | 0.00 |
| Alliance Pharma plc | 183.15m | -33.58m | 240.55m | 290.00 | -- | 1.08 | -- | 1.31 | -0.0622 | -0.0622 | 0.3378 | 0.4124 | 0.4016 | 2.72 | 4.67 | 627,215.80 | -7.36 | -0.5982 | -8.08 | -0.6566 | 59.42 | 62.45 | -18.34 | -1.80 | 2.06 | 4.45 | 0.3218 | -- | 7.92 | 8.86 | -56.24 | -- | -25.01 | -- |
| Golden Throat Holdings Group Co Ltd | 110.32m | 28.75m | 240.70m | 860.00 | 8.37 | 1.71 | 7.29 | 2.18 | 0.381 | 0.381 | 1.46 | 1.86 | 0.4994 | 3.23 | 4.07 | 1,243,848.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| PharmaSGP Holding SE | 91.32m | 15.15m | 241.62m | 93.00 | 15.94 | 8.90 | 10.52 | 2.65 | 1.52 | 1.52 | 9.15 | 2.72 | 0.8223 | 1.04 | 8.57 | 1,233,225.00 | 13.64 | 13.70 | 18.34 | 19.98 | 90.91 | 90.20 | 16.59 | 17.56 | 1.54 | 14.98 | 0.6823 | -- | 17.80 | 10.78 | 37.17 | 2.16 | 25.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Slater Investments Ltd.as of 22 Jul 2024 | 70.68m | 13.07% |
| Lombard Odier Asset Management (Europe) Ltd.as of 09 Oct 2024 | 27.26m | 5.04% |
| Rathbones Investment Management Ltd.as of 06 Oct 2023 | 25.97m | 4.80% |
| Polar Capital LLPas of 03 Sep 2024 | 21.53m | 3.98% |
| Fidelity Management & Research Co. LLCas of 11 Jun 2024 | 19.64m | 3.63% |
| Artemis Investment Management LLPas of 11 Jun 2024 | 17.35m | 3.21% |
| Van Lanschot Kempen Investment Management NVas of 18 Jun 2024 | 15.02m | 2.78% |
| RBC Global Asset Management (UK) Ltd.as of 25 Aug 2023 | 14.55m | 2.69% |
| Bill & Melinda Gates Foundation Trust (Investment Management)as of 03 Sep 2024 | 14.35m | 2.66% |
| Rowan Dartington & Co. Ltd. (Broker)as of 03 Sep 2024 | 13.76m | 2.55% |
